GW Pharmaceuticals PLC (GWPH)

117.59
3.10 2.70
NASDAQ : Health Care
Prev Close 114.45
Open 114.95
Day Low/High 114.66 / 118.08
52 Wk Low/High 35.83 / 120.99
Volume 96.37K
Avg Volume 318.90K
Exchange NASDAQ
Shares Outstanding 25.33M
Market Cap 2.91B
EPS -3.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

GW Pharmaceuticals And Its U.S. Subsidiary Greenwich Biosciences Highlight New Epidiolex® (cannabidiol) Data Released By The American Academy Of Neurology

GW Pharmaceuticals And Its U.S. Subsidiary Greenwich Biosciences Highlight New Epidiolex® (cannabidiol) Data Released By The American Academy Of Neurology

More Detailed Poster Presentation Scheduled for April 25, 2017 at AAN Annual Meeting

GW Pharmaceuticals And Its U.S. Subsidiary Greenwich Biosciences To Present Data On Epidiolex® (cannabidiol) At The 2017 American Academy Of Neurology Annual Meeting

GW Pharmaceuticals And Its U.S. Subsidiary Greenwich Biosciences To Present Data On Epidiolex® (cannabidiol) At The 2017 American Academy Of Neurology Annual Meeting

- New Phase 3 Data in Lennox-Gastaut Syndrome Selected for Inclusion in the Emerging Science Program -

Collect Smokin' Hot Profits From This Marijuana Biotech

Collect Smokin' Hot Profits From This Marijuana Biotech

This innovative biotech offers investors an intriguing play on the medical marijuana business.

Cannabis, Coats, and Social Media: The Good, Bad, and Ugly of 2017's IPOs

Cannabis, Coats, and Social Media: The Good, Bad, and Ugly of 2017's IPOs

In the first quarter of the year we've seen some high-profile IPOs. But they're not all created equal. Here's what investors should keep an eye out for ... and avoid.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMRK, AXTA, DFT, GWPH, LBRDK, LBTYA, RPM Downgrades: CIEN, CRNT, IMO, SUNW, TG, TRIB, USCR Initiations: FBIO Read on to get TheStreet Quant Ratings' detailed report:

Bring On The Rate Hike!: Cramer's 'Mad Money' Recap (Friday 3/10/17)

Bring On The Rate Hike!: Cramer's 'Mad Money' Recap (Friday 3/10/17)

This economy is finally strong enough that a rate hike is natural and necessary, says Jim Cramer.

Burlington Stores, Ross Stores, TJX Companies: 'Mad Money' Lightning Round

Burlington Stores, Ross Stores, TJX Companies: 'Mad Money' Lightning Round

Jim Cramer's bullish on Burlington Stores, Ross Stores and TJX Companies.

Ignore the 'Sessions Effect' and Shun These 2 Over-Hyped Pot Stocks

Ignore the 'Sessions Effect' and Shun These 2 Over-Hyped Pot Stocks

The woes of anti-marijuana Attorney General Jeff Sessions are fueling speculative pot stock buying. But you should avoid these two high flying small fry.

Trump's Anti-Pot Stance Won't Hurt This 'Canna-Business' Stock

Trump's Anti-Pot Stance Won't Hurt This 'Canna-Business' Stock

President Trump's socially conservative administration has vowed to crack down on marijuana, but here's why pot investors shouldn't worry.

3 Reasons Why Marijuana's Momentum Is Stronger than Ever

3 Reasons Why Marijuana's Momentum Is Stronger than Ever

We talk with an industry expert about the outlook of the marijuana industry.

GW Pharmaceuticals Is Set to Benefit as Cannabis Takes on Cancer

GW Pharmaceuticals Is Set to Benefit as Cannabis Takes on Cancer

The applications for the company's proprietary treatments seem endless. How can investors get in, and what are the alternative pot profit-makers?

You Can Also Get High on Marijuana Stocks -- Here's How

You Can Also Get High on Marijuana Stocks -- Here's How

Everyone else is doing it.

Cannabis Stocks Do Not Trade on Earnings, Instead on Pipeline of Drugs

Cannabis Stocks Do Not Trade on Earnings, Instead on Pipeline of Drugs

Cannabis stocks are not affected by the volatility in prices during earnings season and instead trade on positive data such as potential FDA approval on their pipeline of drugs.

Fund Manager High On Marijuana, Zinc as Shelters in Pullback

Fund Manager High On Marijuana, Zinc as Shelters in Pullback

Growth is almost guaranteed in these two areas, says James McDonald of Index Strategy Advisors.

'Mad Money Lightning Round: Schlumberger Is the Best of Breed

'Mad Money Lightning Round: Schlumberger Is the Best of Breed

Cramer is taking Magellan Midstream Partners over EQT Midstream and is waiting for Ionis Pharmaceuticals to go lower.

These Stocks Are Too Hot, in a Bad Way : Jim Cramer's 'Mad Money' Recap

These Stocks Are Too Hot, in a Bad Way : Jim Cramer's 'Mad Money' Recap

Going into earnings what the market needs now is more negativity, Cramer says.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Canadian Marijuana Market More Mature, Outperforms U.S. Market

Canadian Marijuana Market More Mature, Outperforms U.S. Market

The Canadian marijuana market is poised for growth as the number of registered patients continues grows and as licensed producers find innovative ways to create value for its shareholders.

4 Stocks You Can Buy to Profit From the Rising Use of Medical Marijuana

4 Stocks You Can Buy to Profit From the Rising Use of Medical Marijuana

GW Pharmaceuticals has developed cannabis-based therapies for treating epilepsy and multiple sclerosis.

Stocks Back to the Ol' Chop and Grind

Doesn't seem to be much life to the market.

Dow Marches to Another Record Close as S&P 500, Nasdaq Also Rise

Dow Marches to Another Record Close as S&P 500, Nasdaq Also Rise

Stocks enjoyed another strong day on Wall Street as the financial sector pushed the S&P 500 higher.